2021

Proteomics secures major pharmacokinetic testing contract

Proteomics International receives $1.2 million in R&D tax incentive

Notification regarding unquoted securities – PIQ

Issue of Equity Incentives to Employees

Final Director’s Interest Notice

Results of Annual General Meeting

AGM Chairman’s Address and Investor Presentation

FDA advises regulatory pathway for PromarkerD in US

PromarkerD distribution network expands to Britain

Initial Directors’ Interest Notices

Proposed issue of Securities

Director Appointments

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

Change of Directors’ Interest Notices

Exercise of Director Options

Application for quotation of securities

Proteomics International awarded $100,000 manufacturing funding

Quarterly Update September 2021 – Appendix 4C

Notice of Annual General Meeting/Proxy Form

Proteomics Chairman Terry Sweet to retire at 2021 AGM

Clinical utility study demonstrates benefit of PromarkerD testing

Annual Report to shareholders

Appendix 4E – Preliminary Final Report

Corporate Governance Statement and Appendix 4G

Proteomics International contracts Biotem to manufacture PromarkerD test kits

Conference presentation – Australasian Diabetes Congress 2021

Proteomics to collaborate to validate test for endometriosis

Application for quotation of securities

Exercise of Options and Secondary Trading Notice

Quarterly Update June 2021 – Appendix 4C

Manufacturing update and clarification of Abcam engagement

Proteomics International engages Abcam to manufacture PromarkerD reagents

Investor Presentation

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

Update on study presented at ADA Conference

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

CCO and CFO appointed to bolster executive team

Proteomics secures major analytical services contract

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

Proposed issue of Securities

Issue of Options and Secondary Trading Notice

Quarterly Update March 2021 – Appendix 4C

Proteomics files US FDA 513(g) regulatory submission

Proteomics International achieves ISO 13485 certification

Exercise of Options

Investor Presentation

Exercise of Options

Interim Financial Report and Appendix 4D

Response to Price Query

Proteomics International seeks FDA approval for PromarkerD

Update – Proposed issue of Securities – PIQ

Issue of Options and Secondary Trading Notice

Results of Meeting

Quarterly Update December 2020 – Appendix 4C